Chemcrux Enterprises Limited , a key player in the bulk drug intermediates sector, has announced significant corporate developments and financial results for the second quarter of fiscal year 2025-26.

New CFO Appointment

The company's Board of Directors has approved the appointment of Ms. Mruga Gajjar as the new Chief Financial Officer (CFO) and Key Managerial Personnel, effective November 6, 2025. Ms. Gajjar brings a wealth of experience to her new role:

• Over 11 years of experience with CA firms
• 3 years in accounting and finance functions at an Electrical EPC company
• 4 months as Senior Executive - Accounts & Finance at Chemcrux Enterprises

Ms. Gajjar's educational background includes:

• Bachelor's degree in Accounting & Financial Management from M.S. University Vadodara
• Master's degree in Commerce from IGNOU
• Cleared CA Intermediate examination

Financial Performance

The Board of Directors has approved the unaudited standalone and consolidated financial results for Q2 and H1 FY2026. Here are the key highlights of the consolidated financial results:

The company's revenue from operations for Q2 FY2026 stood at INR 1,770.63 lacs, showing a marginal decrease compared to INR 1,775.62 lacs in the same quarter of the previous year. The profit for the period in Q2 FY2026 was INR 21.29 lacs, down from INR 114.75 lacs in Q2 FY2025.

For the half-year ended September 30, 2025, Chemcrux Enterprises reported a total income of INR 3,531.55 lacs, slightly lower than the INR 3,551.15 lacs recorded in H1 FY2025. The profit for the period in H1 FY2026 was INR 30.55 lacs, compared to INR 238.57 lacs in the corresponding period of the previous year.

The company's earnings per share (EPS) for Q2 FY2026 stood at Rs. 0.14, down from Rs. 0.77 in Q2 FY2025. For H1 FY2026, the EPS was Rs. 0.21, compared to Rs. 1.61 in H1 FY2025.

The Board meeting, which commenced at 11:30 A.M. and concluded at 01:45 P.M., also reviewed and approved these financial results as recommended by the Audit Committee.

Chemcrux Enterprises continues to focus on its core business of manufacturing and processing bulk drug intermediates. The company's management is committed to navigating the current market conditions and working towards improved performance in the coming quarters.

Chemcrux Enterprises Limited, a leading chemical manufacturing company, held its 29th Annual General Meeting (AGM) on September 24, 2025, passing several significant resolutions that could shape the company's future. The meeting, conducted through video conferencing, saw shareholders approve key measures including an employee stock option plan and an increase in authorized share capital.

Authorized Share Capital Increase

One of the most notable decisions was the approval to increase the company's authorized share capital. Shareholders gave the green light to raise the authorized share capital from Rs. 15.00 crore to Rs. 20.00 crore, divided into 2 crore equity shares of Rs. 10 each. This move provides Chemcrux Enterprises with additional flexibility for future capital raising activities and potential expansion plans.

Employee Stock Option Scheme

In a bid to attract and retain talent, the company introduced the Chemcrux Enterprises Employee Stock Option Scheme 2025 (ESOP 2025). The scheme, which received shareholder approval, authorizes the granting of 20 lakh stock options of Rs. 10 each to eligible employees. This includes employees of subsidiary companies, associate companies, joint ventures, and group companies, both in India and abroad. The Nomination and Remuneration Committee will administer the scheme, which involves the issuance of new equity shares rather than secondary market acquisitions.

Leadership Continuity

Shareholders also approved the continuation of three key directors' terms:

1. Girishkumar Shah will continue as Executive Chairman upon reaching the age of 70.
2. Sanjay Marathe's term as Managing Director was extended beyond his 70th birthday.
3. Bhanubhai Patel will remain as an Independent Director after turning 75.

These approvals ensure leadership stability and continuity in the company's management.

Other Key Resolutions

• The appointment of M/s. KSPS & Co. LLP as secretarial auditors for a five-year term from FY 2025-26 to FY 2029-30 was ratified.
• Shareholders re-appointed Sidhdhi Shah as a director, who was retiring by rotation.
• A final dividend of 10% (Re. 1 per equity share) for the financial year ended March 31, 2025, was declared.

Voting Results

The resolutions were passed with overwhelming majority, with most receiving over 99% votes in favor. The ESOP scheme, while approved, saw a slightly lower approval rate of 99.83% of votes cast.

The strong shareholder support for these resolutions indicates confidence in Chemcrux Enterprises' management and future strategies. The approved measures, particularly the ESOP scheme and increased share capital, position the company for potential growth and employee retention in the coming years.